Gilead Sciences stock pre-market at EUR 131.75: plus 0.54 percent
Published on 10/01/2026 at 08:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock is at EUR 131.75 pre-market at 8:26 a.m. CEST on October 1, 2026, up 0.54 percent versus the EUR 131.04 prior close at Lang & Schwarz on September 30, 2026.
Gilead before the Xetra open
The bid is EUR 131.30 and the ask is EUR 132.20 at Lang & Schwarz. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Gilead Sciences stock.
Partnership for HIV prevention access
On September 15, 2026, Gilead Sciences, Inc. announced an agreement with the Pan American Health Organization to accelerate access to twice-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis across PAHO member states in Latin America and the Caribbean. The company said the agreement establishes a regional pathway through PAHO’s Regional Revolving Funds and provides a route for 14 countries outside Gilead’s voluntary licensing agreements. Gilead Investor Relations reported that the initiative is part of the company’s broader global access strategy for lenacapavir.
Research center opened in Foster City
Gilead also announced on September 8, 2026, that it had opened a 182,000-square-foot research center at its Foster City headquarters. The facility brings together teams working in oncology, inflammation and research data science and is designed to support approximately 325 employees, including 260 laboratory scientists. The company described the center as part of its planned $32 billion U.S. investment in research, development and manufacturing through 2030. Gilead Investor Relations identified the site as one of three Foster City projects linked to that investment.
